57369-92-3

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Hydrazino 8-trifluoromethyl quinoline is used as a key intermediate in the synthesis of pharmaceutical compounds due to its unique structural features, which can be leveraged to develop new drugs with potential therapeutic benefits.
Used in Agricultural Chemical Synthesis:
In the agricultural sector, 4-Hydrazino 8-trifluoromethyl quinoline serves as a valuable precursor in the creation of agrochemicals, potentially leading to the development of novel pesticides or herbicides.
Used in Anti-Tumor Research:
4-Hydrazino 8-trifluoromethyl quinoline is utilized as a subject of anti-tumor research for its potential to inhibit tumor growth, making it a candidate for further exploration in oncology.
Used in Anti-Inflammatory Studies:
4-HYDRAZINO 8-TRIFLUOROMETHYL-QUINOLINE is also used in anti-inflammatory studies, given its demonstrated ability to reduce inflammation, which could be beneficial in the treatment of various inflammatory conditions.
Used in Heterocyclic Compound Synthesis:
As a building block, 4-Hydrazino 8-trifluoromethyl quinoline is used in the synthesis of heterocyclic compounds, contributing to the advancement of organic chemistry and the discovery of new chemical entities with diverse applications.

InChI:InChI=1/C10H8F3N3/c11-10(12,13)7-3-1-2-6-8(16-14)4-5-15-9(6)7/h1-5H,14H2,(H,15,16)

Upstream product

• 23779-97-7 4-chloro-8-(trifluoromethyl)quinoline 
• 23779-96-6 4-hydroxy-8-trifluoromethylquinoline 

Downstream Products

• 1251938-90-5 4-[(2E)-2-[1-(3-bromophenyl)ethylidene]hydrazinyl]-8-(trifluoromethyl)-quinoline 
• 1251938-89-2 4-[(2E)-2-(1-phenylethylidene)hydrazinyl]-8-(trifluoromethyl)-quinoline 

Relevant academic research and scientific papers

Synthesis of some novel pyrazolo[3,4-d]pyrimidine derivatives as potential antimicrobial agents

The reaction of 4-hydrazino-8-(trifluoromethyl)quinoline (2) with ethoxymethylenecyanoacetate afforded ethyl 5-amino-1-[8-(trifluoromethyl) quinolin-4-yl]-1H-pyrazole-4-carboxylate (3) and that with ethoxymethylenemalononitrile afforded 5-amino-1-[8-(trifluoromethyl)quinolin-4- yl]-1H-pyrazole-4-carbonitrile (5). Compounds 3 and 5 were hydrolyzed to get 5-amino-1-[8-(trifluoromethyl)quinolin-4-yl]-1H-pyrazole-4-carboxylic acid and then reacted with acetic anhydride to afford 6-methyl-1-[8-(trifluoromethyl) quinolin-4-yl]pyrazolo[3,4-d]oxazin-4-one (6), which was condensed with different aromatic amines to give a series of 5-substituted 6-methyl-1-[8- (trifluoromethyl)quinolin-4-yl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones (7). Compounds 3 and 5 also reacted with formamide, urea, and thiourea affording the corresponding pyrazolo[3,4-d]pyrimidines (8-13), respectively. Structures of the products have been determined by chemical reactions and spectral studies. All compounds of the series have been screened for their antibacterial and antifungal activity studies. The results are summarized in Tables 1 and 2.

PLATELET STORAGE METHODS AND COMPOSITIONS

Disclosed are compounds and compositions for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. Also disclosed herein are methods for storing platelets and methods for im

Design, synthesis and characterization of new 1,2,3-triazolyl pyrazole derivatives as potential antimicrobial agents: Via a Vilsmeier-Haack reaction approach

The synthesis of a new series of 3-{5-methyl-1-[2-methyl-3-(trifluoromethyl) phenyl/substituted phenyl]-1H-1,2,3-triazol-4-yl}-1-(aryl)-1H-pyrazole-4-carbaldehyde compounds (5a-n) was carried out via a Vilsmeier-Haack formylation of 4-{(1E)-1-[2-(aryl) hydrazinylidene]ethyl}-5-methyl-1-[2-methyl-3-(trifluoromethyl)phenyl/substituted phenyl]-1H-1,2,3-triazole (4a-n) with a phosphorous oxychloride and DMF mixture. The newly synthesized compounds were characterized using IR, 1H NMR, 13C NMR, mass spectral data and elemental analysis. The newly synthesized compounds were screened for their in vitro anti-bacterial, anti-fungal and anti-oxidant activities. Some of the synthesized compounds displayed a broad spectrum of antimicrobial activities and moderate to good anti-oxidant activities. The anti-bacterial results were further supported by in silico molecular docking studies of these compounds for the inhibition of E. coli MurB enzyme (PDB code: 2MBR) and showed a minimum binding energy and good affinity towards the active pocket comparable with the standard drug Ciproflaxin. Thus, they may be considered as good inhibitors of the E. coli MurB enzyme (PDB code: 2MBR).